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BACKGROUND: Breast cancer anti-oestrogen resistance 4 (BCAR4) was identified in a search for genes involved in anti-oestrogen
resistance in breast cancer. We explored whether BCAR4 is predictive for tamoxifen resistance and prognostic for tumour
aggressiveness, and studied its function.
METHODS: BCAR4 mRNA levels were measured in primary breast tumours, and evaluated for association with progression-free survival
(PFS) and clinical benefit in patients with oestrogen receptor (ERa)-positive tumours receiving tamoxifen as first-line monotherapy for
advanced disease. In a separate cohort of patients with lymph node-negative, ERa-positive cancer, and not receiving systemic adjuvant
therapy, BCAR4 levels were evaluated for association with distant metastasis-free survival (MFS). The function of BCAR4 was studied
with immunoblotting and RNA interference in a cell model.
RESULTS: Multivariate analyses established high BCAR4 mRNA levels as an independent predictive factor for poor PFS after start of
tamoxifen therapy for recurrent disease. High BCAR4 mRNA levels were associated with poor MFS and overall survival, reflecting
tumour aggressiveness. In BCAR4-expressing cells, phosphorylation of v-erb-b2 erythroblastic leukaemia viral oncogene homolog
(ERBB)2, ERBB3, and their downstream mediators extracellular signal-regulated kinase 1/2 and v-akt murine thymoma viral oncogene
homolog (AKT) 1/2, was increased. Selective knockdown of ERBB2 or ERBB3 inhibited proliferation, confirming their role in BCAR4-
induced tamoxifen resistance.
CONCLUSION: BCAR4 may have clinical relevance for tumour aggressiveness and tamoxifen resistance. Our cell model suggests that
BCAR4-positive breast tumours are driven by ERBB2/ERBB3 signalling. Patients with such tumours may benefit from ERBB-targeted
therapy.
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Over three decades, the anti-oestrogen tamoxifen has been the
endocrine treatment of choice for patients with oestrogen receptor
(ERa)-positive breast cancer (Early Breast Cancer Trialists’
Collaborative Group, 1998). As an adjuvant therapy after surgery,
tamoxifen reduces the incidence of relapse. In half of the patients
with recurrent disease, tamoxifen induces an objective clinical
response (Jaiyesimi et al, 1995; Jordan, 1995). However, the cancer
will ultimately progress to hormone-independence that is,
becoming unresponsive to tamoxifen. Despite extensive studies,
the mechanisms involved in resistance are largely unknown
(Dorssers et al, 1995; Clarke et al, 2003; Johnston et al, 2003;
Nicholson et al, 2003; Osborne et al, 2005; Riggins et al, 2007).
Clinically, tamoxifen resistance is associated with poor prog-
nosis and outcome. Thus, understanding of the mechanisms
leading to this resistance is needed for developing new therapies.
Previously, we applied several functional screens to identify genes
involved in anti-oestrogen resistance (Dorssers et al, 1993;
Van Agthoven et al, 1998; Brinkman et al, 2000; Meijer et al,
2006; Van Agthoven et al, 2009b). In one of the screens, we
identified a new gene, breast cancer anti-oestrogen resistance 4
(BCAR4). In the tamoxifen-sensitive ZR-75-1 human breast cancer
cell line, forced expression of BCAR4 induced tamoxifen-resistant
proliferation (Meijer et al, 2006).
To establish the clinical relevance of BCAR4, we investigated its
relationship with tamoxifen resistance and cancer aggressiveness.
In addition, we explored its biological function in vitro.
MATERIALS AND METHODS
RNA isolation, complementary DNA synthesis and
quantification of mRNA transcripts
The isolation of RNA, quantification, complementary DNA
synthesis, and normalisation to reference genes were performed
as described before (Sieuwerts et al, 2005; details in the
Supplementary Materials and Methods). TaqMan gene expression
Assay-on-demand assays were BCAR4 Hs00415922_m1, epidermal
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sgrowth factor receptor (EGFR; Hs01076091_m1), v-erb-b2 erythro-
blastic leukaemia viral oncogene homolog (ERBB)2 (Hs00170433_m1),
ERBB3 (Hs00176538_m1) and ERBB4 (Hs00171783_m1) (Applied
Biosystems International, Nieuwerkerk a/d Ijssel, the Netherlands),
used according to the recommendations of the supplier.
Cell lines
The ZR-75-1 and derived cell lines containing expression vectors
for BCAR4 (ZR/BCAR4; Meijer et al, 2006), BCAR3 (ZR/BCAR3;
Van Agthoven et al, 1998), EGFR (ZR/EGFR; Van Agthoven et al,
1992), v-akt murine thymoma viral oncogene homolog (AKT)1
(ZR/AKT1) and AKT2 (ZR/AKT2; Van Agthoven et al, 2009b),
were cultured as described previously (Van Agthoven et al, 1992).
Western blot analysis and immunoprecipitation
Immunoprecipitation and immunoblotting were performed as
described previously (De Koning et al, 1996, details in the
Supplementary Materials and Methods).
Small interfering RNA-mediated inhibition of gene
expression
Cells were seeded into 96-well plates at a density of 7500 per well.
After 24h, a mixture containing 25ml small interfering RNA
(siRNA), 25ml DharmaFect3 (Perbio-Science, Etten Leur, the
Netherlands), and 50ml medium was added. Final concentrations
were 25nM siRNA, 1nM b-estradiol or 1mM 4-hydroxytamoxifen
(Sigma-Aldrich Chemie, Zwijndrecht, the Netherlands). The
ZR/EGFR cells were cultured in 4-hydroxyamoxifen-containing
medium, with 10ngml
1 EGF (Roche Diagnostics, Almere, the
Netherlands). After 4 days, a WST-1 proliferation assay was
performed (Roche Diagnostics). For each condition, six replicates
were assayed. For RNA isolation, eight replicates were lysed with
RNABee (Bio-Connect, Huissen, the Netherlands) and pooled.
siRNAs were On TARGETplus SMARTpools (Dharmacon,
Perbio-Science), each consisting of three oligonucleotides): EGFR
(L-003114-00-0005), ERBB2 (L-003126-00-005), ERBB3 (L-003127-
00-0005) and ERBB4 (L003128-00-0005).
Clinical details
To assess the clinical relevance of BCAR4 in breast cancer, we
measured mRNA levels in a cohort of 1474 ERa-positive and
-negative primary breast tumours from patients with detailed
clinical follow-up (Van Agthoven et al, 2009a). BCAR4 was
detected in 398 samples (27%). ERa status was determined by
ligand-binding or enzyme immunoassays (Foekens et al, 1989),
73% of the tumours were ERa-positive. The medical ethics
committee of the Erasmus MC-University Medical Center Rotterdam,
the Netherlands, approved our study design (MEC 02.953).
This retrospective study was in accordance with the Code of
Conduct of the Federation of Medical Scientific Societies in the
Netherlands, and is reported in line with the REMARK guidelines
(McShane et al, 2006). All patients underwent surgery between
1979 and 1996.
To determine the association of BCAR4 with tamoxifen
resistance, samples from 280 patients (selected from the cohort
of 1474 patients) with ERa-positive tumours, who received first-
line tamoxifen therapy for advanced disease, were analysed. About
42% of these patients had lymph node-negative cancer and 10%
presented with metastasis at diagnosis. None had received
adjuvant hormone therapy. A total of 53 patients were treated
with systemic adjuvant chemotherapy (21 with anthracycline- and
32 with non-anthracycline-based regimens). Response to tamo-
xifen treatment was monitored according to a standardised
protocol (Hayward et al, 1977; EORTC Breast Cancer Cooperative
Group, 2000). Clinical benefit, defined as objective (measurable)
tumour response or no change for more than 6 months, was
observed in 172 patients (62%) with 11 complete and 37 partial
remissions, and 124 had no change for more than 6 months. From
the remaining 108 patients, 91 had progressive disease and 17 had
no change for 6 months or less. The median follow-up time after
the start of tamoxifen therapy was 38.2 months. The median time
that 50% of the patients experienced progression is 9.2 months.
For studying the relation between BCAR4 mRNA levels and
prognosis, 506 patients with lymph node-negative cancer, ERa
protein-positive disease were selected from the cohort of 1474
patients. None received systemic adjuvant therapy. During
follow-up, 193 experienced a relapse of distant metastasis (median
follow-up time was 97 months). Patients with recurrent disease
(115) were subsequently treated with tamoxifen. These were also
included in the advanced study group of 280 patients.
Statistical analyses
Statistical computations were performed with STATA, 10.1
(STATA Corp., College Station, TX, USA). Differences in mRNA
concentrations were assessed by the Mann–Whitney U test or the
Kruskal–Wallis test. Patient and tumour characteristics were used
as grouping variables. Spearman rank correlation was used to
quantify the strength of the monotonic association between
continuous variables. For the levels of estrogen receptor (ESR)1
and progesterone receptor (PGR), Box-Cox and logarithmic
transformation was applied to reduce skewness. The transformed
data were used for all analyses. The Cox proportional hazards
model was used to calculate the hazard ratio (HR) and its 95%
confidence interval in the analyses for metastasis-free survival
(MFS), overall survival, progression-free survival (PFS) and post-
relapse survival. For MFS, the end point was the first detection of a
distant metastasis as confirmed after symptoms reported by the
patient or at the time of detection of clinical signs at follow-up.
This end point was preferred over relapse-free survival because
relapse may be local and treated accordingly. The group is
therefore more homogeneous from the perspective of treatment.
During the years the tumours were collected (1979–1996), tumour
grade was assessed by regional pathologists and not yet according
current standards. In addition, approximately 30% of the
pathology records lacked information on tumour grade. Therefore,
we included in our prognostic analyses only the univariate survival
data, because grade is included in the model for multivariate
analysis. For all advanced patients treated with tamoxifen, PFS was
defined as the time elapsed between initiation of first-line
tamoxifen therapy and the first detection of disease progression.
In multivariable analyses for PFS, the model included the classical
predictive factors age, menopausal status at start of first-line
therapy, the disease-free interval, the dominant site of relapse and
ESR1 and PGR mRNA levels. Proportional hazards assumption was
verified by a test based on Schoenfeld residuals. In case of
violation, the analysis was stratified for the variable. Data were
visualised in survival curves with the method of Kaplan and Meier.
The logrank test was used to compare survival curves, whereas for
more than two groups the logrank test for trend was used. Logistic
regression analysis was used for the relation between mRNA levels
and clinical benefit of tamoxifen therapy and reported as the odds
ratio and its 95% confidence interval. A two-sided P-value of
o0.05 was considered statistically significant.
RESULTS
Clinical relevance of BCAR4
Association of BCAR4 mRNA levels with tamoxifen resistance To
address the question whether BCAR4 is associated with clinical
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stamoxifen resistance, we studied 280 ERa-positive primary breast
cancer specimens from patients with advanced disease. These
patients received tamoxifen monotherapy as first-line treatment.
The levels of BCAR4 mRNAs were determined by quantitative
RT–PCR of complementary DNA preparations of primary breast
tumours. The levels of BCAR4 mRNA were analysed for association
with the clinicopathological factors and the end points PFS, clinical
benefit and post-relapse survival. BCAR4 mRNA was detected in
81 samples (29%). Tumours with mRNA levels below the detection
limit were categorised as negative. Tumours with detectable levels
of mRNA were categorised in a single group (positive), or in two
groups (low or high) split at median levels. No relation between
categorised BCAR4 mRNA levels and age, menopausal status,
tumour size, nodal status, or adjuvant systemic treatment of the
patients was observed (Supplementary Table 1).
Univariate Cox regression analysis revealed that the presence of
BCAR4 mRNA was significantly associated with shorter PFS (positive
vs negative HR¼1.45, P¼0.007, Table 1). High levels were signi-
ficantly associated with shorter PFS (high vs negative HR¼1.70,
P¼0.003), whereas low levels were not informative. The Kaplan–
Meier curves for PFS in these subgroups show rapid progression of
the disease in patients with high levels of BCAR4 (Figure 1).
In the multivariate analysis for PFS, high BCAR4 levels were
independently predictive for short PFS (high vs negative,
HR¼1.47, P¼0.041, Table 1). In the univariate analysis of post-
relapse survival, high BCAR4 levels were related with poor
outcome (high vs negative HR¼1.68, P¼0.007, Supplementary
Table 2), but this association was not independent of the
traditional predictive factors (HR¼1.44, P¼0.073). In the
univariate logistic regression analysis of clinical benefit, high
BCAR4 levels were significantly associated with an unfavourable
response to tamoxifen treatment (high vs negative odds
ratio¼0.49, P¼0.042, Supplementary Table 3).
Association of BCAR4 mRNA levels with tumour aggressiveness In
our cell line model, expression of BCAR4 gives rise to an aggressive
phenotype, that is, vigorous oestrogen-independent growth and
anchorage independence (Meijer et al, 2006). Therefore, we
investigated whether BCAR4 mRNA levels give information on
tumour aggressiveness. To estimate the true prognostic value of
BCAR4, we performed analyses on a cohort of 506 patients with
lymph node-negative cancer, ERa-positive disease. These patients
Table 1 PFS after first-line tamoxifen treatment of 280 patients with oestrogen receptor-positive primary breast cancer
Univariate analysis Multivariate analysis
No. HR 95% CI P HR 95% CI P
Age at start of therapy (years) 0.083 0.109
p55 110 1.00 1.00
56–70 102 0.85 0.64–1.12 0.74 0.49–1.10
470 68 0.70 0.51–0.96 0.62 0.40–0.96
Menopausal status at start of therapy 0.454 0.216
Pre 73 1.00 1.00
Post 207 0.90 0.68–1.19 1.30 0.86–1.96
Disease-free interval (years)
a o0.001
p1 72 1.00
1–3 126 0.67 0.50–0.90
43 82 0.52 0.37–0.72
Dominant site of relapse 0.673 0.517
Local regional relapse 29 1.00 1.00
Bone 144 1.20 0.79–1.83 1.18 0.76–1.84
Viscera 107 1.15 0.74–1.77 1.29 0.82–2.05
ESR1 mRNA level 280 0.91 0.86–0.96 0.001 0.92 0.86–0.98 0.010
PGR mRNA level 280 0.90 0.84–0.97 0.004 0.92 0.85–0.99 0.026
Additions to the base model
b
BCAR4 280
Positive vs negative 81/199 1.45 1.11–1.90 0.007 1.26 0.95–1.68 0.104
Low vs negative 41/199 1.27 0.90–1.80 0.177 1.12 0.78–1.60 0.554
High vs negative 40/199 1.70 1.20–2.41 0.003 1.47 1.02–2.13 0.041
Abbreviations: CI¼confidence interval; HR¼hazard ratio; PFS¼progression-free survival. BCAR4 mRNA levels were defined as high, low or negative.
aMultivariate analyses
were stratified for this variable.
bBCAR4 was introduced to the base model that included the factors age, menopausal status, dominant site of relapse and ESR1 and PGR mRNA
levels as transformed continuous variables. Inclusion of adjuvant chemotherapy in the base model did not change the estimates for BCAR4.
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Figure 1 Progression-free survival of 280 patients with advanced disease
treated with first-line tamoxifen monotherapy. Kaplan–Meier curves for
PFS for subgroups of patients as a function of BCAR4 mRNA status. Patients
at risk at 12-month intervals are indicated.
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shad not received systemic adjuvant treatment. BCAR4 mRNA was
detected in 119 samples (24%). No relation between categorised
BCAR4 mRNA levels and age, menopausal status, tumour size, or
tumour grade was found (Supplementary Table 4).
Univariate analyses showed a significant association between the
presence of BCAR4 mRNA (positive vs negative) and shorter MFS
(HR¼1.41, P¼0.033) and overall survival (HR¼1.77, P¼0.001;
Table 2). Kaplan–Meier curves show the rapid recurrence of the
disease in the group of patients with detectable BCAR4 compared
with the BCAR4-negative group (Figure 2). Patients with high
BCAR4 in the tumours showed the worst MFS and overall survival
(Table 2).
Characterisation of BCAR4 using a breast cancer model
BCAR4 activates ERBB2 and ERBB3 signalling Identification of
activated proteins in BCAR4-expressing cells may give important
insight into BCAR4 function in anti-oestrogen-resistant prolifera-
tion. To identify proteins activated by BCAR4, we performed
immunoprecipitation using an antibody directed to phosphory-
lated tyrosine residues. Lysates of ZR-75-1 cells were compared
with lysates of equal numbers of cells with forced expression of
BCAR4, BCAR3, AKT1 or AKT2. All these transgenic cell lines are
resistant to tamoxifen, due to expression of the transgene (Van
Agthoven et al, 1998; Brinkman et al, 2000; Meijer et al, 2006; Van
Agthoven et al, 2009b). Among others, an abundant 180-kD band
was detected in ZR/BCAR4 cells, which was hardly observed in the
other cell lines (Figure 3A, arrow). The position of the protein
band and the knowledge that the ERBB receptors can be involved
in tamoxifen resistance provided a possible clue. Identically loaded
blots were probed with antibodies against EGFR, ERBB2, ERBB3
and ERBB4. ZR-75-1 cells do not express EGFR (Van Agthoven
et al, 1992) and phosphorylated EGFR was not detected. Low
levels of phosphorylated ERBB4 were detected, but no increase in
ZR/BCAR4 cells (Figure 3A). In contrast, phosphorylation of
ERBB2 and ERBB3 was noticeably elevated in the ZR/BCAR4 cells
(Figure 3A). This increase in phosphorylation of ERBB2 and
ERBB3 in BCAR4 transduced cells, compared with empty vector-
expressing cells, was not due to higher total levels of these receptor
proteins (Figure 3B). Additional analyses showed that AKT and
extracellular signal-regulated kinase 1/2, representing major
proliferative and survival pathways downstream of ERBB2/ERBB3
signalling, were also activated in ZR/BCAR4 cells (Figure 3B).
Table 2 Univariate analysis for metastasis-free and overall survival in 506 patients with oestrogen receptor-positive, lymph node-negative primary
breast cancer
Metastasis-free survival Overall survival
No. HR 95% CI P HR 95% CI P
Age (years) 0.035 0.479
p40 56 1.00 1.00
41–55 183 0.82 0.54–1.26 0.95 0.58–1.55
56–70 159 0.61 0.39–0.96 0.91 0.55–1.51
470 108 0.53 0.32–0.89 1.26 0.74–0.215
Menopausal status 0.054 0.334
Pre 203 1.00 1.00
Post 303 0.76 0.57–1.01 1.16 0.86–1.58
Tumour size (cm) 0.269 0.232
p2 233 1.00 1.00
42 273 1.17 0.88–1.56 1.20 0.89–1.62
Grade 0.001 0.040
Poor 243 1.00 1.00
Unknown 161 1.11 0.81–1.50 1.00 0.72–1.40
Moderate 102 0.51 0.33–0.78 0.60 0.39–0.93
ESR1 mRNA 506 0.95 0.89–1.01 0.080 0.98 0.92–1.04 0.546
PGR mRNA 506 0.85 0.78–0.93 o0.001 0.84 0.76–0.92 o0.001
BCAR4
Positive vs negative 119/387 1.41 1.03–1.94 0.033 1.77 1.28–2.45 0.001
Low vs negative 60/387 1.29 0.84–1.98 0.240 1.62 1.06–2.48 0.027
High vs negative 59/387 1.54 1.03–2.31 0.037 1.94 1.28–2.94 0.002
Abbreviations: CI¼confidence interval; HR¼hazard ratio; MFS¼metastasis-free survival. BCAR4 mRNA levels were defined as high, low or negative.
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Figure 2 Metastasis-free survival in 506 patients with LNN, ERa-positive
breast cancer. Kaplan–Meier curves for MFS for subgroups of patients as a
function of BCAR4 mRNA status of the primary tumours. Patients at risk at
24-month intervals are indicated.
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ERBB2 and ERBB3 receptors.
siRNA-mediated reduction of ERBB signalling inhibits BCAR4-
induced proliferation If increased ERBB2 and/or ERBB3 signal-
ling is required for BCAR4-induced tamoxifen resistance then
inhibition of ERBB2 and/or ERBB3 should suppress ZR/BCAR4
proliferation. To test this, ZR/BCAR4 and control cell lines were
transfected with small interfering RNAs (siRNA) directed against
the different ERBB receptors. Successful downregulation of ERBB2
was confirmed by western blot analysis (insert, Figure 4A).
Inhibition of all ERBB receptors was verified by quantitative
RT–PCR, showing reductions of over 50% of EGFR in ZR/EGFR
cells, X80% of ERBB2 and ERBB3, and more than 60% for ERBB4
mRNA transcripts.
The ZR-75-1 cells are oestrogen-dependent, and growth is
inhibited by anti-oestrogens. As a consequence, addition of
4-hydroxytamoxifen inhibited proliferation of ZR-75-1 cells,
irrespective of the addition of siRNA (Figure 4A). Knockdown of
EGFR expression did not inhibit proliferation of ZR/BCAR4 cells,
due to the fact that both our parental and ZR/BCAR4 cells are
devoid of EGFR. However, ERBB2, ERBB3, and ERBB4 siRNA all
significantly inhibited proliferation of ZR/BCAR4 cells in the
presence of 4-hydroxytamoxifen (Figure 4A). In the presence of
EGF, ZR/EGFR cells are resistant to tamoxifen due to the
expression of the EGFR transgene (Van Agthoven et al, 1992).
Proliferation was reduced when EGFR was inhibited by siRNA-
mediated interference (Figure 4A) confirming the involvement of
this pathway in resistance of these cells. The knockdown of ERBB2
and ERBB4, but not ERBB3, in ZR/EGFR cells also resulted in the
inhibition of proliferation.
In oestradiol-containing medium, proliferation of BCAR4-
expressing cells was also inhibited by addition of ERBB2 or ERBB3
siRNA (Figure 4B). In contrast, knocking down ERBB2 or ERBB3
expression in the vector-control cells did not inhibit proliferation.
In the presence of oestrogen, ZR/EGFR cells use the oestrogen
receptor pathway and are not further stimulated with EGF. As
expected, knockdown of EGFR in the presence of oestradiol did
not inhibit proliferation (Figure 4B). In oestradiol-containing
medium, proliferation of ZR-75-1, ZR/BCAR4 and ZR/EGFR cells
was reduced by knockdown of ERBB4, suggesting a role of ERBB4
in oestrogen-regulated growth (Figure 4B).
DISCUSSION
We describe two sets of patients with ERa-positive breast cancer.
The first group received tamoxifen as first-line treatment for
advanced disease. This allowed for the analysis of clinical benefit,
PFS and post-relapse survival in advanced breast cancer patients in
relation to BCAR4 mRNA levels in the primary tumour. In the
second group, including only patients with lymph node-negative
cancer, ERa-positive breast cancer, we investigated the prognostic
value of BCAR4 mRNA levels. Our data show that high BCAR4
levels are independently predictive for shorter PFS after start of
first-line tamoxifen therapy and in addition provide prognostic
information for MFS and overall survival. Our results indicate that
patients with high levels of BCAR4 are at increased risk for early
recurrence of the disease and have reduced probability of long-
term benefit of tamoxifen treatment.
We show that ERBB2/ERBB3 signalling is critically involved in
the mechanism of BCAR4-induced proliferation in the presence of
oestrogen or tamoxifen. The overexpression of BCAR4 induced
strong phosphorylation of ERBB2 and ERBB3. Key downstream
mediators of ERBB signalling, AKT and extracellular signal-
regulated kinase 1/2, were also activated in BCAR4-transduced
cells. The siRNA-mediated inhibition of the ERBB receptors
confirmed the direct involvement of ERBB2 and ERBB3 in
BCAR4-mediated proliferation. The ERBB tyrosine kinase recep-
tors have important roles in normal development, growth, and
differentiation. Their involvement in numerous types of human
tumours has been reported (for review, see Holbro et al, 2003).
Gene amplification and overexpression of ERBB2 has been
reported in several types of cancer, including the breast cancer,
and has been shown to contribute to a poor clinical outcome
pTYR
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ZR/AKT1
ZR/AKT2
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Figure 3 Activation of the ERBB2/ERBB3 signalling pathway by BCAR4.
(A) Lysates of ZR-75-1 cells transduced with empty vector, BCAR4, BCAR3,
AKT1 or AKT2 were immunoprecipitated with phosphotyrosine-specific
antibody and subjected to western blot analysis. An approximately 180-kD
band in lysates from ZR/BCAR4 cells is marked with an arrow. To identify
the phosphorylated proteins in this band, identically loaded blots were
probed with antibodies against EGFR, ERBB2, ERBB3 and ERBB4. Phospho-
EGFR was not detected (data not shown). (B) Activation of downstream
signalling of ERBB2/ERBB3. Lysates of two independent pools of ZR-75-1
cells containing empty vector or stably expressing BCAR4, cultured in the
presence of oestradiol (E) or 4-OHT (T), were subjected to western blot
analysis. Blots were probed with total ERBB2, ERBB3, phospho-AKT, total-
AKT, phospho-extracellular signal-regulated kinase (ERK)1/2 and total-
ERK1/2 antibodies and b-actin for loading control.
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s(Slamon et al, 1989; Gullick et al, 1991; Seshadri et al, 1993; Berns
et al, 1995; Liu et al, 2007; Van Agthoven et al, 2009a).
Overexpression or amplification of ERBB2 predicts response
failure to tamoxifen therapy (Wright et al, 1992; Berns et al,
1995; Dowsett et al, 2001; Hurtado et al, 2008; Van Agthoven et al,
2009a). In patients with hormone receptor-positive breast cancer
who had received adjuvant tamoxifen therapy, EGFR, ERBB2 and
ERBB3 phosphorylation was observed to be associated with shorter
disease-free and overall survival (Frogne et al, 2009).
We have shown a mechanistic relationship between BCAR4
and the ERBB2/ERBB3 signalling pathways in the development
of anti-oestrogen resistance in vitro. Therefore, BCAR4 expres-
sion may identify a subgroup of patients with increased ERBB2/
ERBB3 signalling, independent of gene amplification and/or over
expression of ERBB2. This is particularly important because
currently the application of ERBB2-targeting drugs is limited to
patients whose tumours express high levels of the ERBB2 protein
or show amplification of the ERBB2 gene (Hynes and Lane, 2005).
Tumours with activated ERBB2 signalling via other mechanisms
than amplification or over expression will be tested ERBB2-
negative. These patients are currently withheld ERBB2-targeting
drugs. However, it remains to be established whether BCAR4-
positive primary tumours have elevated levels of phosphorylated
ERBB2 or ERBB3.
The BCAR4 amino-acid sequence predicts two transmembrane
domains, suggesting it may be localised at the cell membrane.
Therefore, it might be a ligand for ERBB3, stimulating ERBB2/
ERBB3 activity. It could also be a substrate for membrane-bound
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Figure 4 Knockdown of ERBB receptors reduces proliferation of cells with forced expression of BCAR4 or EGFR.( A) Cells were exposed to 4-hydroxy
tamoxifen (OH-TAM), plus EGF for ZR/EGFR cells. Insert shows the down-regulation of ERBB2 protein by western blot analysis, 96h after treatment with
siERBB2 (þ) or transfection reagent only ( ). (B) Proliferation was measured in oestradiol (E2)-containing medium. Bars represent the average of
6 independent siRNA transfections. Data of six replicates is reported as mean±s.d.. Significance was determined by the Mann-Whitney U test; *Po0.05,
**Po0.01 compared to the control (medium without siRNA).
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domain family of proteins, some of them reported to be expressed
in several cancers, including the breast cancer, in which they may
release ERBB ligands and promote proliferation (for review, see
Mochizuki and Okada, 2007). Another possible mechanism could
be an intracellular interaction with the different ERBB receptors
inducing their phosphorylation, as reported for nucleolin (Di Segni
et al, 2008). The BCAR4 protein could also function similarly to
Mucin4 that was reported to be a transmembrane ligand for ERBB2
(for review, see Carraway et al, 2001). Another ability of Mucin4 is
to translocate ERBB2 to the apical surface in polarised epithelial
cells (Ramsauer et al, 2003), or to increase the amount of ERBB2
and ERBB3 in the plasma membrane, by preventing their
intracellular accumulation (Funes et al, 2006). How BCAR4
activates ERBB2/ERBB3 signalling remains to be established.
In conclusion, high levels of BCAR4 mRNA predict resistance to
endocrine therapy and poor outcome in ERa-positive breast
cancer. If BCAR4-positive tumours are driven by ERBB2 signalling,
in the absence of gene amplification or overexpression, as our
results suggest, then more patients may benefit from ERBB2-
directed therapy.
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